Key Drivers
- Liquidity Strength
- R&D Burden
- Ongoing Burn
AIAI Summary
IDYA has shifted from a survival-risk biotech to a late-stage oncology story with nearly $1B in cash and real regulatory momentum behind darovasertib, but the investment now hinges on whether upcoming data and NDA execution can convert that funding runway into a durable commercial asset before dilution or a clinical miss resets the thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Strength
- •R&D Burden
- •Ongoing Burn
IDYA's liquidity and solvency are strong, but persistent losses, heavy R&D spend, and ongoing cash burn continue to outweigh its high gross margins and low leverage.
Price Behavior
Key Price Behavior Insights:
- •Higher base
- •Breakout support
- •Extended rally
IDYA's last month has been decisively constructive, with a strong rally to a fresh high after forming a higher base and holding breakout support in the mid-$36s, though the move is extended and volatile with first resistance near the upper-$37s to $38.
Sharp swings and a quick drop-recovery in early
Sentiment & News
Key News Insights:
- •Capital raise
- •Darovasertib progress
- •IDE892 launch
IDEAYA raised up to $300 million, advanced darovasertib and IDE892 in key oncology milestones, and refreshed leadership as it strengthened its pipeline and balance sheet.
The financing and clinical updates support IDEAYA's near-term execution and pipeline momentum, though the new share issuance may weigh on sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings